.svg)
If you’ve tried multiple antidepressants without success, you’re not alone. Many people living with depression struggle to find relief. That’s why the FDA-approved Spravato® (esketamine) nasal spray offers a groundbreaking new option for those battling treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts.
Spravato® (esketamine) is a form of ketamine delivered through a nasal spray, administered under medical supervision in a certified healthcare setting. Unlike traditional antidepressants that can take weeks or months to work, Spravato often produces rapid relief from depressive symptoms—even within hours to days for some patients.
Spravato works differently by targeting the NMDA receptors in the brain, helping restore healthy brain function and improve mood.
Novel Mechanism → Unlike SSRIs and SNRIs, Spravato acts on glutamate pathways in the brain.
Rapid Onset → Many patients experience symptom relief within the first few treatments.
Neuroplasticity → Spravato may help rebuild brain connections damaged by chronic depression.
Spravato® (esketamine) works differently by targeting the NMDA receptors in the brain, helping restore healthy brain function and improve mood.
Spravato is FDA-approved for:
→ Adults with treatment-resistant depression (TRD)
→ Adults with major depressive disorder (MDD)
To qualify for Spravato, patients must have tried at least two other antidepressants without sufficient improvement.
